You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Topic 375: 18F PET Tracer For Imaging PD-L1 (Moonshot)

    SBC: SIBTECH, INC.            Topic: NCI

    New therapies, designed to enhance anti-tumor immunity are based on the blockade of the checkpoint components, either PD-1 on immune cells or PD-L1 on tumor cells. This strategy, while being spectacularly successful in some patients for some cancers, fails for many other patients. The expression of PD-L1 is highly dynamic and its prevalence within tumors can vary significantly over time. The curre ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. A Method to Increase Buprenorphine Treatment Capacity and Effectiveness

    SBC: CBT4CBT, LLC            Topic: R42

    The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioiddependent patientsOvermillion people in the US are addicted to opiatesProviding effective agonist therapymethadone or buprenorphinecoupled with behavioral counseling greatly improves outcomesreduces morbidityand reduces societal costsMethadone maintenance treatment has been limited due to complex sta ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma

    SBC: ONCOARENDI THERAPEUTICS LLC            Topic: NHLBI

    Approximatelymillion Americans suffer from asthmawhich leads to aboutdeaths per yearand is responsible for estimated annual total direct and indirect costs of $billionDespite the existing treatments for asthmapredominantly combinations of inhaledagonists and corticosteroidsCSsthere remains a significant unmet medical need for new therapies which address two key issuesapproximatelyof patients are i ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Multifunctional Antioxidant to Prevent Noise-Induced Hearing Loss

    SBC: Therapeutic Vision, Inc.            Topic: NIDCD

    Noise induced hearing lossNIHLis the most common occupational disease for which no clinically effective drug is availableSince NIHL involves oxidation linked loss of sensory hair cells and auditory neurons in the cochleathere is a need for potent and effective antioxidants that offer protection to these tissuesIn preliminary studies we have observed that the orally administered multifunctional ant ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. An antigen-detection assay to diagnose Babesia microti infection

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    Project Summary Human babesiosis is a malaria like multisystem disease caused primarily by Babesia microtian emerging apicomplexan parasite that infects and develops within human erythrocytesThe parasite is transmitted to humans by the tick vector Ixodes scapularis and can also be introduced through blood transfusionInfection can cause flu like symptomsand severe infection can be fatalin particula ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a hybrid transcatheter mitral valve replacement and repair device

    SBC: Dura LLC            Topic: NHLBI

    PROJECT SUMMARYMitral regurgitationMRis the most prevalent valvular heart disease in the U Saffecting approximatelyof the populationThere aremillion patients in the US with moderate to severe MR requiring treatmentHoweveronly approximatelypatients in the U Sundergo surgery for MR each year due to concerns about procedural complexity and patient safetyThere is great enthusiasm among the heart valve ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Bioengineered skin microbiota for cutaneous mitigation of Netherton Syndrome

    SBC: Azitra Inc.            Topic: NIAMS

    PROJECT SUMMARY Current treatment options for many skin diseases especially rare diseases fail to address the underlying causative pathophysiologiesIn the case of genetic mutations that cause loss of function mutationssupplementing the missing protein is a viable approach to treatmentHoweverdelivery of functional protein to the target keratinocytes presents a significant challengemoreoverthe cost ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Seromic Mucin Signature for the Early Diagnosis of Pancreatic Cancer

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: 102

    ABSTRACT Pancreatic cancerPCis an extremely aggressive malignancy with one of the worst prognoses of all cancersWith marked resistance to chemoand radiotherapiessurgery is the only curative optionIn patients with localized diseasecomplete surgical resection provides five year survival rate ofHoweverandgtof patients are diagnosed with unresectable primary tumors and or distant metastasisThe major c ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government